Screener
CytomX Therapeutics CTMX Total debt
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $5.7M.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
FAQ
- What is CytomX Therapeutics's total debt?
- CytomX Therapeutics (CTMX) reported total debt of $5.7M in Q2 2026.
- How has CytomX Therapeutics's total debt changed year-over-year?
- CytomX Therapeutics's total debt decreased by 17.2% year-over-year, from $6.89M to $5.7M.
- What is the long-term trend for CytomX Therapeutics's total debt?
- Over 5 years (2020 to 2025), CytomX Therapeutics's total debt has grown at a -29.8% compound annual growth rate (CAGR), from $24.87M to $4.24M.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.
Ask your AI about CytomX Therapeutics's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude